Cencora, Inc. (COR) News
Follow Cencora, Inc. (COR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 55 public stories across 21 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Cencora Shares Rise 2% Premarket After 2027 Earnings Forecast Raised
Cencora shares rose 2% in premarket trading after its 2027 earnings forecast was raised.
EQUITY | Nov 04, 2026, 01:15 PM UTC
M
Cencora Reports Fiscal Q4 2026 Results, Provides FY2027 Guidance
Revenue was $88.35 billion and adjusted EPS was $4.66, both above FactSet consensus. Cencora forecast FY2027 adjusted EPS of $19.40 to $19.75 and increased its quarterly dividend.
EQUITY | Nov 04, 2026, 01:03 PM UTC
M
Cencora Reports Q4 Net Income of $519.4 Million
Cencora reported fourth-quarter net income attributable to the company of $519.4 million, compared with a loss of $339.7 million a year earlier. Profit per share was $2.71 versus a loss of $1.75.
EARNINGS | Nov 04, 2026, 12:30 PM UTC
M
Cencora Sees FY27 Adjusted EPS at $19.40–$19.75
EARNINGS | Nov 04, 2026, 11:47 AM UTC
M
Cencora Beats Q4 EPS by $0.08, Guides FY27 In Line
Cencora reported Q4 earnings of $4.66 per share, excluding non-recurring items, $0.08 above expectations. It guided FY27 EPS and revenue in line.
EARNINGS | Nov 04, 2026, 11:44 AM UTC
M
Cencora Q4 revenue reaches $88,354.53 million
Cencora reported Q4 revenue of USD 88,354.53 million versus the IBES estimate of USD 88,030 million.
EQUITY | Nov 04, 2026, 11:43 AM UTC
M
Cencora reports fourth-quarter revenue of $88.35 billion
EQUITY | Nov 04, 2026, 11:43 AM UTC
L
Cencora Reports Q4 Net Income of $529.1 Million
EARNINGS | Nov 04, 2026, 11:42 AM UTC
M
Cencora Returns to Net Profit in FY26 Fourth Quarter
Cencora reported a return to net profit in the fourth quarter of FY26.
EARNINGS | Nov 04, 2026, 11:42 AM UTC
M
Cencora Reports Fourth-Quarter Adjusted EPS of $4.66
EARNINGS | Nov 04, 2026, 11:40 AM UTC
M
Cencora Reports Q4 Adjusted EPS of USD 4.66
Cencora’s Q4 adjusted EPS was USD 4.66, versus the IBES estimate of USD 4.58.
EARNINGS | Nov 04, 2026, 11:39 AM UTC
M
Cencora Sees FY27 Adjusted Free Cash Flow of About $3.5B
EARNINGS | Nov 04, 2026, 11:39 AM UTC
L
Cencora Q4 EPS USD 2.71
EARNINGS | Nov 04, 2026, 11:39 AM UTC
M
Cencora Q4 Adjusted Operating Income $1.2 Billion, Below Estimate
Cencora reported fourth-quarter adjusted operating income of USD 1,200 million versus the IBES estimate of USD 1,238 million.
EARNINGS | Nov 04, 2026, 11:39 AM UTC
M
Cencora Sees FY27 Distribution and Services Revenue Up 4%-6%
Cencora expects pharmaceutical distribution and services revenue to rise 4%-6% in FY27.
EARNINGS | Nov 04, 2026, 11:38 AM UTC
M
Cencora Reports Fiscal 2026 Fourth-Quarter and Full-Year Results
EQUITY | Nov 04, 2026, 11:35 AM UTC
M
Cencora Reports Fourth-Quarter Net Income of $519.4M
EARNINGS | Nov 04, 2026, 11:35 AM UTC
L
Cencora Reports 4Q EPS of $2.71
EARNINGS | Nov 04, 2026, 11:35 AM UTC
M
Cencora Q4'26 Earnings Preview Includes EPS Estimate
Cencora is scheduled to report Q4'26 results before market open on November 4. Revenue and EPS estimates were provided.
EQUITY | Nov 03, 2026, 12:01 PM UTC
M
Novatio Solutions Completes Arbour Group Acquisition
Novatio Solutions completed its acquisition of Arbour Group to expand its life sciences services.
MNA | Oct 29, 2026, 04:12 PM UTC
M
Cencora to Acquire American Oncology Network for $2.4 Billion
Cencora agreed to acquire American Oncology Network in a deal valued at USD 2.4 billion.
EQUITY | Oct 29, 2026, 04:12 PM UTC
L
Sanofi settles U.S. antitrust lawsuit over Lantus
Sanofi settled a U.S. antitrust lawsuit concerning competition for its diabetes drug Lantus.
REGULATION | Oct 28, 2026, 08:42 PM UTC
M
Cencora Q4'26 Earnings Preview
Cencora is scheduled to report Q4'26 results on November 4 before the market opens. Revenue and EPS estimates are provided in the source.
EQUITY | Oct 28, 2026, 11:00 AM UTC
M
Cencora to Buy American Oncology Network in Deal Valuing It at Up to $2.4 Billion
Cencora said it would acquire American Oncology Network in a deal valuing the cancer care provider at up to $2.4 billion, expanding its presence in community oncology across the United States.
MNA | Oct 21, 2026, 04:02 PM UTC
M
Cencora to Acquire American Oncology Network for Up to $2.4 Billion
Cencora said it would acquire American Oncology Network in a deal valuing the cancer care provider at up to $2.4 billion.
EQUITY | Oct 21, 2026, 01:35 PM UTC
M
Cencora to Acquire American Oncology Network
EQUITY | Oct 21, 2026, 12:25 PM UTC
M
Cencora to Acquire American Oncology Network in Definitive Agreement
Cencora said it signed a definitive agreement to acquire AON, a physician-led network of more than 350 oncology providers across 21 states.
EQUITY | Oct 21, 2026, 11:37 AM UTC
M
Cencora Expects to Pay About $1.7B to Raise AON Stake to 75%
Cencora expects to pay about $1.7 billion to increase its ownership in AON to 75%, assuming certain stockholders retain 25% through an equity rollover.
MNA | Oct 21, 2026, 11:34 AM UTC
M
Cencora transaction values AON at $2.4B enterprise value
The transaction includes $2.3B at closing and contingent value rights of up to $100M.
MNA | Oct 21, 2026, 11:33 AM UTC
H
Cencora Q3 2026 Earnings Call Transcript
Cencora (NYSE: COR ) held its third-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you APIs. For real-time access to our entire catalog, pleas
LIVE | Oct 08, 2026, 09:53 AM UTC
M
Cencora to Release Q4 Earnings on November 4
Cencora announced it will release its fourth-quarter financial results on Wednesday, November 4, before the market opens.
EQUITY | Oct 02, 2026, 02:19 PM UTC
M
Cencora announces fourth-quarter fiscal 2026 earnings date
Cencora said it will announce fourth-quarter fiscal 2026 earnings on the scheduled date and time.
EQUITY | Oct 02, 2026, 12:02 PM UTC
L
Camino Minerals Corporation (COR) Wins Peru Approval to Expand Costa de Cobre Exploration
Camino received MINEM approval for the Second MEIA-sd at Costa de Cobre, expanding the area ~94% and permitting up to 280 drill platforms and up to 611,840m of drilling across three copper trends. Drilling is planned to
COMMODITIES | Sep 28, 2026, 10:01 AM UTC
L
Robert E. Sanchez appointed to Cencora board effective Oct 1, 2026
Cencora appointed Robert E. Sanchez to its Board of Directors, effective October 1, 2026, increasing the board from ten to eleven members.Original SEC Filing: Cencora, Inc. [ COR ] - 8-K - Sep. 25, 2026This is an AI-powe
REGULATION | Sep 25, 2026, 12:14 PM UTC
L
Cencora, Inc. (COR) Elects Robert E. Sanchez to Board
Cencora, Inc. elected Robert E. Sanchez, Executive Chair of Ryder and former CEO, as an independent director effective Oct 1, 2026.Material DetailsContext by AI AnalystThis is a governance update adding logistics depth t
NEWS | Sep 25, 2026, 12:01 PM UTC
L
Cencora Elects Robert E. Sanchez to Its Bd of Directors
Cencora Elects Robert E. Sanchez to Its Bd of Directors
NEWS | Sep 25, 2026, 12:01 PM UTC
L
Cencora Elects Robert E. Sanchez to Its Board of Directors
Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026.Mr. Sanchez is the Executive Chair of Ryder System, Inc., where
NEWS | Sep 25, 2026, 12:00 PM UTC
L
Estoril Sol: Fozpatrimonio Now Holds 32.7% Share Capital In Co
Estoril Sol SGPS SA EURONEXT:ESON
NEWS | Sep 15, 2026, 04:29 PM UTC
L
COR: Specialty-driven growth and MSO integration position the business for sustained momentum through 2027
Strong specialty pharma growth is expected to continue through 2027, driven by focused investments in oncology and retina, integration of MSO platforms, and robust international performance. Regulatory and customer dynam
NEWS | Sep 15, 2026, 01:50 PM UTC
L
COR: Specialty focus and MSO integration drive growth, with robust capital and regulatory management
Strong specialty-driven growth continues, with confidence in long-term momentum through 2027. Integration of OneOncology and RCA enhances clinical trial capabilities, while regulatory and customer dynamics remain well ma
MNA | Sep 15, 2026, 01:21 PM UTC
L
COR: Specialty growth, biosimilars, and MSO expansion fuel strong performance amid stable partnerships
Specialty pharmaceuticals and oncology drive strong growth, with international operations rebounding and strategic relationships remaining stable. Minor Walgreens volume shifts were anticipated, and biosimilars, AI, and
EQUITY | Sep 08, 2026, 03:06 PM UTC
L
Cencora price target maintained at $330 by RBC Capital
RBC Capital maintained its $330.00/share price target for Cencora.
EQUITY | Sep 08, 2026, 02:47 PM UTC
H
COR: Specialty and oncology growth, stable guidance, and innovation drive strong performance
Specialty pharmaceuticals and oncology drive strong growth, with international and MSO segments performing well. Guidance incorporates minor Walgreens volume shifts, and biosimilars and innovation offer ongoing tailwinds
EQUITY | Sep 08, 2026, 02:32 PM UTC
H
Corpus Resources PLC reports results of AGM resolutions
Corpus Resources Plc says that at its AGM held 4 September 2026 at 09:00 am, all resolutions were decided.
EARNINGS | Sep 04, 2026, 11:31 AM UTC
L
Camino closes brokered placement and non-brokered convertible debentures
Camino says it has closed a brokered private placement of units alongside a non-brokered private placement of convertible debentures.
EQUITY | Aug 26, 2026, 03:40 PM UTC
L
BMO, Wedbush, Wolfe and RBC issue stock initiations
BMO, Wedbush, Wolfe, RBC and Cantor initiate coverage with ratings changes on AKTS, ALNY, ASND, BCAX, BMRN, CATX, PRME, AFL, AGMB, COR and MCK.
EQUITY | Aug 19, 2026, 11:09 AM UTC
H
Cencora Reaffirms FY26 EPS Guidance
Cencora reaffirms FY26 adjusted diluted EPS guidance of $17.75-$17.95
EARNINGS | Aug 12, 2026, 04:46 PM UTC
H
Terrible Jobs Report Sparks Rally In AI and Tech: 10 Stocks Leading Friday's Surge
Bad news was once again good news for Wall Street. A surprisingly weak U.S. jobs report sent investors rushing back into speculative technology stocks Friday, as slowing labor-market momentum fueled hopes the Federal Res
CENTRAL_BANK | Aug 07, 2026, 01:37 PM UTC
H
Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins
Cencora Inc. (NYSE: COR ) on Wednesday reported third-quarter adjusted earnings of $4.48 per share, beating the consensus of $4.35. The pharmaceutical solutions organization reported sales of $84.754 billion, up 5.1% yea
EARNINGS | Aug 05, 2026, 04:44 PM UTC
H
COR - Cencora Reports Fiscal 2026 Third Quarter Results
COR - Cencora Reports Fiscal 2026 Third Quarter Results
EARNINGS | Aug 05, 2026, 10:32 AM UTC
H
Cencora Raises FY2026 Adj EPS Guidance from $17.70-$17.90 to $17.75-$17.95 vs $17.79 Est; Affirms FY2026 Sales Guidance of $334.152B-$340.57
Cencora (NYSE: COR ) raises FY2026 Adj EPS guidance from $17.70-$17.90 to $17.75-$17.95 vs $17.79 analyst estimate. Affirms FY2026 sales outlook from $334.152 billion-$340.578 billion to $334.152 billion-$340.578 billion
EARNINGS | Aug 05, 2026, 10:31 AM UTC
M
Insiders Buy COR, KYN, AMS
Insiders purchase shares of COR, KYN, AMS, and other companies
EQUITY | Jun 25, 2026, 09:47 AM UTC
M
Insiders Buy COR, KYN, AMS, F, YYGH
Insiders purchase shares of COR, KYN, AMS, F, and YYGH with total amounts exceeding $100K
EQUITY | Jun 24, 2026, 09:04 PM UTC
L
COR Director Buys
COR Director purchases 4,000 shares at $274.19
EQUITY | Jun 23, 2026, 09:24 AM UTC
L
COR: Director Buys
Cencora, Inc. Director Dermot Mark P Durcan buys 4,000 shares at $274.19
EQUITY | Jun 22, 2026, 08:06 PM UTC